Myriad Genetics Return on Equity

Myriad Genetics (MYD.DE) currently reports a ROE of -37.05%. That is above the Healthcare sector average of -75.59%. Use the charts on this page to explore Myriad Genetics's ROE history and peer comparisons.

Myriad Genetics's ROE of -37.05% is higher than the Healthcare sector average of -75.59%. That is roughly 51.0% above the sector mean. A reading higher peers can reflect different growth expectations, capital structure, or profitability — so it is worth checking the peer comparison chart before drawing conclusions.

There is no universal 'good' ROE, but Myriad Genetics's current -37.05% should be judged against Healthcare norms (sector average: -75.59%) and against MYD.DE's own history. Strong, stable readings often indicate durable competitive advantage; volatile or declining ones deserve a closer look at margins and capital efficiency.

Start with the current ROE of -37.05%, then check the historical chart for trend and the peer comparison chart for relative positioning. The Healthcare average is -75.59%. From there, open related valuation or income-statement pages for Myriad Genetics, and consider following MYD.DE for alerts when major investors trade the stock.

Myriad Genetics is classified in the Healthcare sector. On ROE, it currently shows -37.05% versus a sector average near -75.59%. Sector peers often share similar capital intensity and growth regimes, so relative rankings inside Healthcare are usually more informative than comparing MYD.DE with unrelated industries.